DB05649InvestigationalProtein Based Therapies
NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the... In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.
- Primary indication
- Investigated for use/treatment in strokes.Curator reviewed
- Code names
- NTx-265
What you can answer from here — as of April 08, 2025
Which companies are running trials of NTx-265, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account